The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Phase II Study of Weekly Docetaxel and Trastuzumab for Patients With HER-2–Overexpressing Metastatic Breast Cancer
Abstract
PURPOSE: To evaluate the safety and efficacy of weekly docetaxel plus trastuzumab in women with HER-2–overexpressing metastatic breast cancer. Efficacy was correlated with serum HER-2 extracellular domain (ECD) levels. PATIENTS AND METHODS: Thirty women with metastatic breast cancer were treated with weekly docetaxel and trastuzumab as first- or second-line therapy. Both docetaxel 35 mg/m 2/wk and trastuzumab 2 mg/kg/wk were delivered in 4-week cycles consisting of three weekly treatments followed by 1 week of rest. A loading dose of trastuzumab 4 mg/kg was administered 1 day before the start of the first cycle. RESULTS: The median delivered dose-intensity of docetaxel was 24 mg/m 2/wk (range, 18 to 27 mg/m 2/wk). The intent-to-treat overall response rate (ORR) was 63% (95% confidence interval [CI], 44% to 80%). The ORR in patients whose tumors were HER-2–positive by fluorescence in situ hybridization was 67% (16 of 24 patients; 95% CI, 45% to 84%). In patients with elevated serum HER-2 ECD at baseline, the ORR was 76% (95% CI, 53% to 92%), compared with 33% (95% CI, 7% to 70%) in patients with low HER-2 ECD levels (P = .04). Variations in HER-2 ECD concentrations during treatment correlated with response to treatment. Median time to progression was 9 months. Acute toxicity, including myelosuppression, was mild. Fatigue, fluid retention, and excessive tearing became more common with repetitive dosing. CONCLUSION: Weekly docetaxel and trastuzumab is an active combination for treating patients with HER-2–overexpressing metastatic breast cancer. Serum HER-2 ECD testing may be a promising method for monitoring patients on trastuzumab-based therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1992) · Springer Series in Statistics · doi:10.1007/978-1-4612-4380-9_25 · Cited by 45,181
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1958) · Journal of the American Statistical Association · doi:10.1080/01621459.1958.10501452 · Cited by 39,158
Slamon, D. J., Clark, G. M., Wong, S. G., Levin, W. J., Ullrich, A., & McGuire, W. L. (1987) · Science · doi:10.1126/science.3798106 · Cited by 11,760
Toxicity and response criteria of the Eastern Cooperative Oncology Group
Oken, M. M., Creech, R. H., Tormey, D. C., Horton, J., Davis, T. E., McFadden, E. T., & Carbone, P. P. (1982) · AMERICAN JOURNAL OF CLINICAL ONCOLOGY · doi:10.1097/00000421-198212000-00014 · Cited by 11,647
Slamon, D. J., Leyland-Jones, B., Shak, S., Fuchs, H., Paton, V., Bajamonde, A., Fleming, T., Eiermann, W., Wolter, J., Pegram, M., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200103153441101 · Cited by 11,500
Cobleigh, M. A., Vogel, C. L., Tripathy, D., Robert, N. J., Scholl, S., Fehrenbacher, L., Wolter, J. M., Paton, V., Shak, S., Lieberman, G., et al. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.9.2639 · Cited by 2,765
Baselga, J., Tripathy, D., Mendelsohn, J., Baughman, S., Benz, C. C., Dantis, L., Sklarin, N. T., Seidman, A. D., Hudis, C. A., Moore, J., et al. (1996) · Journal of Clinical Oncology · doi:10.1200/jco.1996.14.3.737 · Cited by 1,380
Similarity of protein encoded by the human c-erb-B-2 gene to epidermal growth factor receptor
Yamamoto, T., Ikawa, S., Akiyama, T., Semba, K., Nomura, N., Miyajima, N., Saito, T., & Toyoshima, K. (1986) · Nature · doi:10.1038/319230a0 · Cited by 1,204
Amplification of a Novel v- erb B-Related Gene in a Human Mammary Carcinoma
King, C. R., Kraus, M. H., & Aaronson, S. A. (1985) · Science · doi:10.1126/science.2992089 · Cited by 1,072
Pegram, M. D., Lipton, A., Hayes, D. F., Weber, B. L., Baselga, J. M., Tripathy, D., Baly, D., Baughman, S. A., Twaddell, T., Glaspy, J. A., et al. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.8.2659 · Cited by 1,067
Chan, S., Friedrichs, K., Noel, D., Pintér, T., Van Belle, S., Vorobiof, D., Duarte, R., Gil Gil, M., Bodrogi, I., Murray, E., et al. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.8.2341 · Cited by 641
Seidman, A. D., Fornier, M. N., Esteva, F. J., Tan, L., Kaptain, S., Bach, A., Panageas, K. S., Arroyo, C., Valero, V., Currie, V., et al. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.10.2587 · Cited by 547
Self-citationSchechter, A. L., Hung, M.-C., Vaidyanathan, L., Weinberg, R. A., Yang-Feng, T. L., Francke, U., Ullrich, A., & Coussens, L. (1985) · Science · doi:10.1126/science.2992090 · Cited by 518
Andrulis, I. L., Bull, S. B., Blackstein, M. E., Sutherland, D., Mak, C., Sidlofsky, S., Pritzker, K. P., Hartwick, R. W., Hanna, W., Lickley, L., et al. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.4.1340 · Cited by 441
Valero, V, Holmes, F. A., Walters, R. S., Theriault, R. L., Esparza, L., Fraschini, G., Fonseca, G. A., Bellet, R. E., Buzdar, A. U., & Hortobagyi, G. N. (1995) · Journal of Clinical Oncology · doi:10.1200/jco.1995.13.12.2886 · Cited by 386
Self-citationBurstein, H. J., Kuter, I., Campos, S. M., Gelman, R. S., Tribou, L., Parker, L. M., Manola, J., Younger, J., Matulonis, U., Bunnell, C. A., et al. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.10.2722 · Cited by 366
Pegram, M. D., Finn, R. S., Arzoo, K., Beryt, M., Pietras, R. J., & Slamon, D. J. (1997) · Oncogene · doi:10.1038/sj.onc.1201222 · Cited by 332
Ravdin, P. M., Burris, H. A., Cook, G., Eisenberg, P., Kane, M., Bierman, W. A., Mortimer, J., Genevois, E., & Bellet, R. E. (1995) · Journal of Clinical Oncology · doi:10.1200/jco.1995.13.12.2879 · Cited by 317
Jacobs, T. W., Gown, A. M., Yaziji, H., Barnes, M. J., & Schnitt, S. J. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.7.1974 · Cited by 302
Pestalozzi, B. C., & Brignoli, S. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.11.2349 · Cited by 301
Docetaxel Administered on a Weekly Basis for Metastatic Breast Cancer
Burstein, H. J., Manola, J., Younger, J., Parker, L. M., Bunnell, C. A., Scheib, R., Matulonis, U. A., Garber, J. E., Clarke, K. D., Shulman, L. N., et al. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.6.1212 · Cited by 260
Yamauchi, H., O'Neill, A., Gelman, R., Carney, W., Tenney, D. Y., Hösch, S., & Hayes, D. F. (1997) · Journal of Clinical Oncology · doi:10.1200/jco.1997.15.7.2518 · Cited by 239
Trastuzumab and chemotherapeutics: drug interactions and synergies.
Pegram, M. D., Lopez, A. M., Konecny, G., & Slamon, D. (2000) · PubMed · Cited by 174
HER2 overexpression and paclitaxel sensitivity in breast cancer: therapeutic implications.
Baselga, J. M., Seidman, A. D., Rosen, P. P., & Norton, L. (1997) · PubMed · Cited by 157
Immunohistochemical Determination of HER-2/neu Expression in Invasive Breast Carcinoma
VANG, R. S., Cooley, L. D., Harrison, W. R., Reese, T., & Abrams, J. (2000) · American Journal of Clinical Pathology · doi:10.1309/ltum-qg95-yry3-l96u · Cited by 30
Cited by
Trastuzumab — Mechanism of Action and Use in Clinical Practice
Hudis, C. A. (2007) · New England Journal of Medicine · doi:10.1056/nejmra043186 · Cited by 2,585
Harris, L., Fritsche, H., Mennel, R., Norton, L., Ravdin, P., Taube, S., Somerfield, M. R., Hayes, D. F., & Bast, R. C. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.2364 · Cited by 2,217
Self-citationNagata, Y., Lan, K.-H., Zhou, X., Tan, M., Esteva, F. J., Sahin, A. A., Klos, K. S., Li, P., Monia, B. P., Nguyen, N. T., et al. (2004) · Cancer Cell · doi:10.1016/j.ccr.2004.06.022 · Cited by 1,858
“…oligonucleotides (12.5 nM for BT474 and 25 nM for SKBr3 cells) twice using trastuzumab plus taxane (paclitaxel or docetaxel) (Esteva et al., 2002; Seid-Oligofectamine (Life Technologies, Rockville, MD) 24 and 72 hr postplating. man et al., 2001).”
BackgroundMethodInfluentialMarty, M., Cognetti, F., Maraninchi, D., Snyder, R., Mauriac, L., Tubiana-Hulin, M., Chan, S., Grimes, D., Antón, A., Lluch, A., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.173 · Cited by 1,597
Bendell, J. C., Domchek, S. M., Burstein, H. J., Harris, L., Younger, J., Kuter, I., Bunnell, C., Rue, M., Gelman, R., & Winer, E. (2003) · Cancer · doi:10.1002/cncr.11436 · Cited by 1,320
Metadata
- Authors
- Esteva, F. J., Valero, V., Booser, D., Guerra, L. T., Murray, J. L., Pusztai, L., Cristofanilli, M., Arun, B., Esmaeli, B., Fritsche, H. A., Sneige, N., Smith, T. L., & Hortobagyi, G. N.
- Venue
- Journal of Clinical Oncology
- Published
- 2002-04-01
- Volume
- 20
- Issue
- 7
- Pages
- 1800-1808
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2146406055
- Cited by
- 566
- References
- 25
- FWCI
- 18.37
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.